Nexavar is an oral multi-kinase inhibitor jointly developed by Bayer HealthCare and Onyx Pharmaceuticals, which targets both the tumor cell and tumor vasculature. In Japan, Nexavar is the first approved oral targeted therapy for metastatic renal cell carcinoma.
Gunnar Riemann, member of the board of management of Bayer Schering Pharma, said: “This approval of Nexavar is a crucial step for patients with advanced kidney cancer in Japan. This is also a major accomplishment for the company’s oncology franchise in Japan.”